UNSPSC 51332301: Axamozide

This classification denotes an antipsychotic agent with the molecular formula C21H22ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MCG9O55T6K, chemically known as ( -)-1-(1-(1,4-benzodioxan-2-ylmethyl)-4-piperidyl)-5-chloro-2-benzimidazolinone but generally known as axamozide, which bears US NIH Compound Identifier 170359. European Medicines Agency schedules Axamozide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05621MIG.

UNSPSC 51332301 Axamozide is a Commodity code that captures pharmaceutical active ingredients and chemical compounds used in state and local healthcare, public health, and emergency response applications. Recent state and local solicitations under this code reflect procurement of naloxone (opioid-reversal medication), generic multi-source pharmaceuticals, and over-the-counter products distributed through authorized wholesalers to support community health initiatives, pharmacy benefit programs, and emergency medical services. State and local buyers include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. The work spans direct procurement of finished pharmaceutical products through traditional competitive bidding, establishment of master supply agreements with pricing tied to national drug codes and authorized distributor networks, and exploratory market-intelligence gathering to design direct-to-manufacturer prescription fulfillment programs.

Issuing bodies span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate purchasing cooperatives (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota and Oregon). Recent solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, due July 26, 2023; the Texas HHS Commission's Request for Information on direct-to-manufacturer prescription programs, posted April 3, 2026; and MMCAP's Request for Proposal for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, and awarded vendors to be available through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) by May 15, 2026. Contracts typically require compliance with cGMP, FDA registration, Drug Supply Chain Security Act certification, comprehensive insurance including commercial general liability coverage, and E-Verify eligibility confirmation. Geographic activity centers on Florida, Texas, and the Midwest, with cooperative purchasing extending across multiple states.